Blair William & Co. IL Boosts Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Blair William & Co. IL raised its stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 14.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,101,325 shares of the company’s stock after acquiring an additional 136,273 shares during the period. Blair William & Co. IL’s holdings in Poseida Therapeutics were worth $3,216,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Poseida Therapeutics by 89.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after acquiring an additional 391,801 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Poseida Therapeutics during the fourth quarter worth about $169,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Poseida Therapeutics by 177.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after purchasing an additional 40,245 shares during the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Trading Down 6.6 %

Shares of Poseida Therapeutics stock opened at $3.37 on Monday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48. The company has a market capitalization of $327.33 million, a P/E ratio of -2.83 and a beta of 0.51. Poseida Therapeutics, Inc. has a 1 year low of $1.83 and a 1 year high of $4.27. The company’s fifty day moving average is $3.11 and its two-hundred day moving average is $2.95.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The firm had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative return on equity of 121.01% and a negative net margin of 127.48%. Analysts forecast that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.